ALK upgrades its full-year revenue and earnings outlook ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial...
ALK provides update on regulatory process for the house dust mite allergy tablet in China ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced...
ALK launches new growth strategy and 2028 financial ambitions ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors...
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies At the Annual Congress of the...
ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review ALK (ALKB:DC / OMX: ALK B / AKBLF) today...
Listen in on ALK’s Capital Markets Day on 4 June 2024 ALK (ALKB:DC / OMX: ALK B / AKBLF) will host a Capital Markets Day on 4 June at...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.